Prognostic Significance of Lymph Node Examination by the OSNA Method in Lung Cancer Patients-Comparison with the Standard Histopathological Procedure.
Biomarkers, Tumor
/ genetics
Disease-Free Survival
Female
Follow-Up Studies
Humans
Immunohistochemistry
/ methods
Keratin-19
/ genetics
Lung Neoplasms
/ diagnosis
Lymph Nodes
/ pathology
Lymphatic Metastasis
Male
Neoplasm Metastasis
Neoplasm Staging
Nucleic Acid Amplification Techniques
/ methods
Prognosis
Prospective Studies
Treatment Outcome
E
H&
IHC CK19
OSNA
lung cancer
lymph nodes
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
04 12 2020
04 12 2020
Historique:
received:
26
10
2020
revised:
26
11
2020
accepted:
01
12
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
7
2021
Statut:
epublish
Résumé
The aim of the study was to compare the prognostic significance of lymph node status of patients with lung cancer analyzed by three different methods: hematoxylin and eosin (H&E), immunohistochemistry of cytokeratin 19 (IHC CK19), and One-Step Nucleic Acid Amplification (OSNA). The clinical relevance of the results was evaluated based on relation to prognosis; the disease-free interval (DFI) and overall survival (OS) were analyzed. During radical surgical treatment, a total of 1426 lymph nodes were obtained from 100 patients, creating 472 groups of nodes (4-5 groups per patient) and examined by H&E, IHC CK19 and OSNA. The median follow-up was 44 months. Concordant results on the lymph node status of the H&E, IHC CK19 and OSNA examinations were reported in 78% of patients. We recorded shorter OS in patients with positive results provided by both OSNA and H&E. The study demonstrated a higher percentage of detected micrometastases in lymph nodes by the OSNA method. However, the higher sensitivity of the OSNA, with the cut-off value 250 copies of mRNA of CK19/µL, resulted in a lower association of OSNA positivity with progress of the disease compared to H&E. Increasing the cut-off to 615 copies resulted in an increase in concordance between the OSNA and H&E, which means that the higher cut-off is more relevant in the case of lung tumors.
Identifiants
pubmed: 33291819
pii: cells9122611
doi: 10.3390/cells9122611
pmc: PMC7762050
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Keratin-19
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Ann Thorac Cardiovasc Surg. 2014;20(3):181-4
pubmed: 23603642
Br J Cancer. 2012 May 8;106(10):1675-81
pubmed: 22531630
Ann Surg Oncol. 2014 Nov;21(12):3924-30
pubmed: 24912612
Clin Lung Cancer. 2019 May;20(3):e346-e355
pubmed: 30665872
Cancer. 2012 Dec 15;118(24):6039-45
pubmed: 22684906
Lung Cancer. 2014 Dec;86(3):318-23
pubmed: 25453845
PLoS One. 2013;8(3):e58823
pubmed: 23533593
Head Neck. 2017 Sep;39(9):1864-1868
pubmed: 28644540
Eur J Cancer. 2013 Apr;49(6):1187-95
pubmed: 23265708
Lung Cancer. 2012 Dec;78(3):212-8
pubmed: 23026640
J Surg Oncol. 2019 Mar;119(3):361-369
pubmed: 30508294
Breast. 2013 Apr;22(2):162-167
pubmed: 23375856
J Surg Oncol. 1994 Nov;57(3):139-42
pubmed: 7967601
Br J Cancer. 2014 May 13;110(10):2544-50
pubmed: 24722182
J Surg Oncol. 2018 Feb;117(2):163-170
pubmed: 29205350
PLoS One. 2017 Feb 10;12(2):e0171517
pubmed: 28187209
J Thorac Oncol. 2009 May;4(5):568-77
pubmed: 19357537
Int J Clin Oncol. 2017 Feb;22(1):3-10
pubmed: 27549784
Cells. 2020 Sep 25;9(10):
pubmed: 32992913
Hum Pathol. 2016 Feb;48:132-41
pubmed: 26614398
Eur J Surg Oncol. 2014 Feb;40(2):150-7
pubmed: 24378008
Ann Med Surg (Lond). 2019 Aug 21;46:17-22
pubmed: 31485327
J Clin Pathol. 2014 Aug;67(8):702-6
pubmed: 24906358
Lung Cancer. 2016 Jul;97:1-7
pubmed: 27237020
J Cell Physiol. 2019 Dec;234(12):21425-21435
pubmed: 31042009
Jpn J Clin Oncol. 2013 Mar;43(3):264-70
pubmed: 23293371
Int J Cancer. 2012 May 15;130(10):2377-86
pubmed: 21780107
Ann Surg Oncol. 2018 Dec;25(13):3812-3819
pubmed: 30203406